

**URINARY TRANSFORMING GROWTH  
FACTOR-BETA 1 AND ALPHA 1-  
MICROGLOBULIN IN CHILDREN AND  
ADOLESCENTS WITH TYPE-1 DIABETES**

*Thesis*

*Submitted for Partial Fulfillment of  
Master Degree in pediatrics medicine*

BY

***Nesreen Ahmed Mahmoud***

***M.B.,B.Ch. Misr International University For Science And  
Technology – July( 2002)***

*Supervised by*

**Prof. Nagham Mohamed Samy El-Beblawy**

*Professor of Pediatrics Medicine  
Faculty of Medicine - Ain Shams University*

**Dr. Amira Abd El-Monem Adly**

*Lecturer of Pediatrics Medicine  
Faculty of Medicine - Ain Shams University*

**Dr Amal Ahmed Abbas**

*Lecturer of Clinical Pathology  
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine  
Ain Shams University  
2007**

# عامل النمو المحول البولى بيتا 1 والمايكروجلوبولين الفا1 فى الاطفال والمراهقين المصابين بداء السكرى

رسالة عملية توطئة للحصول على درجة الماجستير فى طب الاطفال  
مقدمة من

الطبيب/ نسرين أحمد محمود

بكالوريوس الطب والجراحة جامعة مصر للعلوم والتكنولوجيا يوليو 2002

تحت إشراف

أ.د/ نغم محمد سامي الببلاوي

أستاذ الأطفال - كلية الطب - جامعة عين شمس

د/ أميرة عبد المنعم عدلى

مدرس الأطفال - كلية الطب - جامعة عين شمس

د/ أمل أحمد عباس

مدرس الباثولوجيا الاكلينيكية - كلية الطب - جامعة عين شمس

كلية الطب - جامعة عين شمس

2007

## *Contents*

	<i>Page</i>
INTRODUCTION.....	1
AIM OF THE WORK.....	5
REVIEW OF LITERATURE:	
• Type 1 Diabetes Mellitus.....	6
• Diabetic Nephropathy.....	46
• Transforming Growth Factor Beta.....	76
• Alpha-1 Microglobulin.....	87
PATIENTS AND METHODS.....	93
RESULTS.....	115
DISCUSSION.....	145
SUMMARY AND CONCLUSION .....	160
RECOMMENDATIONS.....	164
REFERENCES.....	165
ARABIC SUMMARY.....	

## **List of Tables**

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
1	Official criteria for the diagnosis of DM.....	8
2	Some features of impaired glucose tolerance and/or impaired fasting glucose.....	9
3	Aetiological classification of DM.....	10
4	Complications of type 1 diabetes	26
5	Some causes of inadequate metabolic control in type 1 diabetes.....	28
6	Comparison between the studied groups as regards the demographic data and clinical data.....	116
7	Comparison between the studied groups as regards their metabolic control.....	118
8	Comparison between Normoalbuminuric diabetic patients versus controls as regard TGF beta 1 levels.....	121
9	Comparison between microalbuminuric diabetic patients versus controls as regard TGF beta 1 levels.....	123
10	Comparison between the normoalbuminuric and microalbuminuric diabetic patients as regards urinary TGF beta 1 level.....	125
11	Comparison between normoalbuminuric diabetic patients and the controls group as regards urinary microglobulin alpha-1 level.....	126
12	Comparison between the microalbuminuric diabetic patients and the controls group as regards urinary Microglobulin alpha-1 level .....	127
13	Comparison between the normoalbuminuric and the microalbuminuric diabetic patients as regard urinary Microglobulin alpha-1 level .....	128
14	Correlation between urinary TGF beta-1 level versus laboratory data among microalbuminuric diabetic patients.....	130
15	Correlation between urinary TGF beta-1 level versus laboratory data among normoalbuminuric diabetic patients.....	131

*Continued*

<b><i>Table No.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
16	Correlation between urinary TGF beta-1 level versus urinary microglobulin alpha-1 level among controls group.....	132
17	Correlation between urinary TGF beta-1 level and demographic and clinical data among microalbuminuric diabetic patients.....	133
18	Correlation between urinary TGF beta-1 level and age, disease duration, weight,height and BP among normoalbuminuric diabetic patients .....	134
19	Correlation between urinary microglobulin alpha-1 level and parameters of metabolic control among microalbuminuric diabetic patients.....	135
20	Correlation between urinary microglobulin alpha-1 level and the parameters of diabetic control among normoalbuminuric diabetic patients.....	136
21	Correlation between urinary microglobulin alpha-1 level and age, weight, height and BP among the studied diabetic patients.....	137
22	Correlation between urinary microglobulin alpha-1level versus age, weight, height and BP among the controls group.....	138
23	Correlation between urinary Microglobulin alpha-1 level and urinary TBG beta-1 level versus gender of diabetic patients.....	139
24	Correlation between urinary Microglobulin alpha-1 level and urinary TBG beta-1 level versus gender of controls group .....	140
25	Correlation between urinary Microglobulin alpha-1 level and urinary TBG beta-1 level versus diabetic ketoacidosis attacks among diabetic patients.....	141
26	Sensitivity, specificity, PPV and NPV of the studied markers for prediction of early renal affection among diabetic patients.....	144

## **List of Figures**

<b><i>Fig. No.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
1	Comparison between the studied groups as regards blood pressure.....	117
2	Comparison between the studied groups as regards mean in insulin dosage and mean HBA1c.....	119
3	Comparison between the studied groups as regards the mean RBS.....	120
4	Comparison between TGF beta 1 level in urine of normoalbuminoric diabetic patients and the control group .....	122
5	Comparison between TGF beta 1 level in urine of normoalbuminoric diabetic patients and the control group.....	124
6	Comparison between Microglobulin Alpha 1 level in urine among the studied groups .....	129
7	Receiver operator characteristic curve (ROC) for detection of the best cut off value and area under the curve for TGF beta 1 level in urine in prediction of early renal affection among diabetic patients.....	142
8	Receiver operator characteristic curve (ROC) for detection of the best cutoff value and area under the curve for Microglobulin alpha-1 level in urine in prediction of early renal affection among diabetic cases.....	143

## **List of Abbreviations**

ACE.....	Angiotensin Converting Enzyme
ACR.....	Albumin Creatinine Ratio
ARBs.....	angiotensin II type 1-receptor blockers
BMP.....	Bone morphogenetic protein
CD.....	Cluster of differentiation
COOPERATE.....	Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting- Enzyme Inhibitor in Nondiabetic Renal Disease
CTLA.....	cytotoxic T lymphocyte antigen
DCCT.....	The Diabetes control and Complications Trial
DIDMOAD syndrome.....	Diabetes insipidus, diabetes mellitus, optic atrophy, deafness
DM.....	Diabetes Mellitus
DPT-1.....	The Diabetes Prevention Trial – type 1
ELISA.....	Enzyme Linked Immunosorbent Assay
ENDIT.....	The European Nicotinamide Diabetes Intervention Trial
EURODIAB.....	European Diabetes
FPG.....	Fasting plasma glucose
GAD.....	glutamic acid decarboxylase
GFR.....	Glomerular Filtration Rate
Hb.....	Hemoglobin
HBV.....	Hepatits B Virus
HCV.....	Hepatits C Virus
HIV.....	Human Immuno-difficiency Virus
HLA.....	Human leukocyte antigen
HOT.....	Hypertension Optimal Treatment
IDDM.....	Insulin dependent Diabetes Mellitus
IFG.....	Impaired fasting glucose
IGT.....	Impaired glucose tolerance
LAP.....	latency-associated peptide

***Continued***

LDL.....	Low density lipoprotein
LLC.....	large latent complex
LTBP.....	latent TGF- $\beta$ binding protein
LTBP.....	latent TGF- $\beta$ 1 binding protein
MDRD.....	Modification of Diet in Renal Disease Trial
MICRO-HOPE.....	Heart Outcomes Prevention Evaluation
MIS.....	Mullerian inhibitory substance
mRNA.....	Messenger ribonucleic acid
NIDDM.....	Non insulin dependent Diabetes Mellitus
OGTT.....	Oral glucose tolerance test
RAS.....	Renin angiotensin system
RBP.....	Retinol binding protein
SP.....	signal peptide
TGF.....	Transforming growth factor
UAE.....	Urinary albumin excretion
UKPDS.....	United Kingdom prospective diabetes study



# Introduction

---

## Introduction

---

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic nephropathy is categorized into stages: microalbuminuria (UAE >20 µg/min and ≤199 µg/min) and macroalbuminuria (UAE ≥200 µg/min). Hyperglycemia, increased blood pressure levels, and genetic predisposition are the main risk factors for the development of diabetic nephropathy. Elevated serum lipids, smoking habits, and the amount and origin of dietary protein also seem to play a role as risk factors. (*Jorge L. et al., 2005*).

Screening for microalbuminuria should be performed yearly, starting 5 years after diagnosis in type 1 diabetes or earlier in the presence of puberty or poor metabolic control. In patients with type 2 diabetes, screening should be performed at diagnosis and yearly thereafter. Patients with micro- and macroalbuminuria should undergo an evaluation regarding the presence of comorbid associations, especially retinopathy and macrovascular disease. Achieving the best metabolic control (A1c <7%), treating hypertension (<130/80 mmHg or <125/75 mmHg if proteinuria >1.0 g/24 h and increased serum creatinine), using drugs with blockade effect on the renin-angiotensin-aldosterone system, and treating dyslipidemia (LDL cholesterol <100 mg/dl) are effective strategies for preventing the development of microalbuminuria, in delaying

the progression to more advanced stages of nephropathy and in reducing cardiovascular mortality in patients with type 1 and type 2 diabetes (*Jorge L. et al., 2005*).

Improvements in glycemic control and the greater use of antihypertensive therapy should eventually have a beneficial impact on the incidence of severe nephropathy in type 1 diabetes. However, early disease, such as microalbuminuria and macroalbuminuria, will continue to occur because glycemic control cannot wholly prevent the progression of albuminuria, and there is currently little evidence that antihypertensive use in normotensive normoalbuminuric patients is of clinical value. Both microalbuminuria and macroalbuminuria significantly increase the risk of morbidity and mortality from coronary heart disease and are strong predictors of subsequent severe renal disease. Prevention of the early stages of diabetic renal disease and reduction in progression should now be priorities, but these steps require a more complete understanding of the etiology to identify suitable targets for intervention (*Nish C. et al., 2002*)

Diabetic nephropathy is characterized by hypertrophy of the glomerular and tubuloepithelial structures and thickening of the glomerular and tubular basement membrane, due largely to the effects of hyperglycemia . The cytokine transforming growth factor (TGF)- $\beta$ 1 appears to be a key mediator for these changes . TGF- $\beta$ 1 expression is enhanced in the presence of diabetes, either as a direct consequence of hyperglycemia or indirectly via the formation of early or advanced glycation end products . Hyperglycemia stimulates condensation reactions

between glucose and proteins, and an early product of this reaction is an Amadori protein (*Nish C. et al., 2002*).

Transforming growth factor- 1 (TGF- 1) is a potent multifunctional polypeptide that is involved in normal renal function and in the development of glomerular sclerosis. It is also an important mediator of the immune and anti-inflammatory responses (*Pierina De Muro., 2004*).

TGF- represents a group of 25-kD proteins that are actively involved in the development and differentiation of various tissues and in the healing process after a tissue injury . Three isoforms of TGF- have been identified in mammalian species and TGF- 1 is the most commonly found in humans. Normally, TGF- 1 release ceases by feedback mechanisms when the healing process has been completed . However, if TGF- 1 release is not switched off, extracellular matrix components (ECM) are accumulated and tissue fibrosis occurs . TGF- 1 is involved in the development of scarring in crescentic nephritis via activation of myofibroblasts from glomerular parietal epithelial cells . Interstitial myofibroblasts also contribute to the development of fibrous crescents through their migration into the Bowman's space of glomeruli with disrupted capsules . The implication of TGF- 1 is further supported by the observation of amelioration of histologic damage in experimentally induced anti-GBM nephritis with the blockade of TGF- 1 action (*Dimitrios S Goumenos et al., 2005*).

Since the discovery of the central role of transforming growth factor (TGF)- in fibrotic kidney disease , urinary TGF-

activity has been studied in experimental models of kidney disease together with renal TGF- mRNA and protein expression, and indexes of fibrosis . A simultaneous increase in urinary TGF-and glomerular TGF- mRNA and protein was observed in a rabbit model of an antibody- mediated crescentic nephritis. In people with various glomerular diseases, urinary TGF- correlated with the grade of interstitial fibrosis. In patients with membranous glomerulonephritis, urinary TGF- 1 at baseline was lower in those patients who later reached remission than in patients whose disease had a more progressive course. In type 2 diabetic patients, urinary TGF-1 is elevated and associated with histologically proven severe mesangial expansion (*Korpinen E. et al., 2000*).

# Aim of the Work

## **AIM OF THE WORK**

---

The aim of our work is study the urinary TGF-  $\beta_1$  excretion in children and adolescents with type-1 diabetes and its relation with the 2 conventional markers of glomerular and tubular injury; urinary albumin and  $\beta_2$ -microglobulin. Also to assess the relation between urinary TGF-  $\beta_1$  excretion with parameters of glycemic control as HbA1c.